» Articles » PMID: 16682272

Negative Signaling in Fc Receptor Complexes

Overview
Journal Adv Immunol
Date 2006 May 10
PMID 16682272
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Cell activation results from the transient displacement of an active balance between positive and negative signaling. This displacement depends in part on the engagement of cell surface receptors by extracellular ligands. Among these are receptors for the Fc portion of immunoglobulins (FcRs). FcRs are widely expressed by cells of hematopoietic origin. When binding antibodies, FcRs provide these cells with immunoreceptors capable of triggering numerous biological responses in response to a specific antigen. FcR-dependent cell activation is regulated by negative signals which are generated together with positive signals within signalosomes that form upon FcR engagement. Many molecules involved in positive signaling, including the FcRbeta subunit, the src kinase lyn, the cytosolic adapter Grb2, and the transmembrane adapters LAT and NTAL, are indeed also involved in negative signaling. A major player in negative regulation of FcR signaling is the inositol 5-phosphatase SHIP1. Several layers of negative regulation operate sequentially as FcRs are engaged by extracellular ligands with an increasing valency. A background protein tyrosine phosphatase-dependent negative regulation maintains cells in a "resting" state. SHIP1-dependent negative regulation can be detected as soon as high-affinity FcRs are occupied by antibodies in the absence of antigen. It increases when activating FcRs are engaged by multivalent ligands and, further, when FcR aggregation increases, accounting for the bell-shaped dose-response curve observed in excess of ligand. Finally, F-actin skeleton-associated high-molecular weight SHIP1, recruited to phosphorylated ITIMs, concentrates in signaling complexes when activating FcRs are coengaged with inhibitory FcRs by immune complexes. Based on these data, activating and inhibitory FcRs could be used for new therapeutic approaches to immune disorders.

Citing Articles

Regulation of BCR-dependent germinal center B-cell formation by HGAL and insight into its emerging myeloid ortholog, C1ORF150.

Toran P, Novelli A, Lazor J, Vachon A, Wojchowski D Front Immunol. 2024; 15:1437516.

PMID: 39474423 PMC: 11518702. DOI: 10.3389/fimmu.2024.1437516.


Current development of Fc gamma receptors (FcγRs) in diagnostics: a review.

Gan S, Tye G, Chew A, Lai N Mol Biol Rep. 2024; 51(1):937.

PMID: 39190190 DOI: 10.1007/s11033-024-09877-9.


Antibody feedback regulation.

Heyman B Immunol Rev. 2024; 328(1):126-142.

PMID: 39180190 PMC: 11659925. DOI: 10.1111/imr.13377.


Phagocytosis.

Uribe-Querol E, Rosales C Methods Mol Biol. 2024; 2813:39-64.

PMID: 38888769 DOI: 10.1007/978-1-0716-3890-3_3.


On the complexity of IgE: The role of structural flexibility and glycosylation for binding its receptors.

Plattner K, Bachmann M, Vogel M Front Allergy. 2023; 4:1117611.

PMID: 37056355 PMC: 10089267. DOI: 10.3389/falgy.2023.1117611.